Keyphrases
Fusion Gene
100%
Acute Myeloid Leukemia
100%
RUNX1-ETO
100%
Nanoparticles
100%
Small Interfering RNA (siRNA)
50%
Knockdown
33%
Malignancy
16%
Therapeutic Target
16%
Drug Development
16%
Leukemia
16%
Clinical Setting
16%
Gene Expression
16%
Mouse Model
16%
Self-renewal
16%
Further Development
16%
Runt-related Transcription Factor 1 (RUNX1)
16%
Myeloid Differentiation
16%
Engraftment
16%
Therapeutic Targeting
16%
Median Survival
16%
Lipid Nanoparticles
16%
Chromosomal Rearrangements
16%
Clonogenicity
16%
Conventional Drugs
16%
Leukemia Mice
16%
Long-range Inhibition
16%
Transcriptomic Changes
16%
Clinical Support
16%
In Vivo Delivery
16%
Biochemistry, Genetics and Molecular Biology
RUNX1
100%
Myeloid
100%
Fusion Gene
100%
Small Interfering RNA
33%
Gene Expression
16%
Mouse Model
16%
Lipid
16%
Transcriptomics
16%
Chromosomal Rearrangement
16%
Clonogenesis
16%
Cofactor
16%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
Nanoparticle
100%
Small Interfering RNA
75%
Mouse Model
25%
Leukemia
25%
Solid Lipid Nanoparticle
25%
Drug Development
25%